Provided by Tiger Fintech (Singapore) Pte. Ltd.

United Therapeutics

295.52
-4.6400-1.55%
Post-market: 295.520.00000.00%17:23 EDT
Volume:300.70K
Turnover:89.23M
Market Cap:13.33B
PE:11.77
High:298.96
Open:298.19
Low:295.33
Close:300.16
Loading ...

Renaissance Technologies: Inside the Machine of Quantitative Mastery

TradingKey
·
11 Jul

United Therapeutics Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
11 Jul

United Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
08 Jul

J.P. Morgan Sticks to Their Buy Rating for United Therapeutics (UTHR)

TIPRANKS
·
08 Jul

United Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
01 Jul

United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says

MT Newswires Live
·
30 Jun

UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating

MT Newswires Live
·
30 Jun

Paul A. Mahon, EVP & General Counsel, Reports Disposal of United Therapeutics Corp Common Shares

Reuters
·
28 Jun

United Therapeutics Shareholders Approve Key Resolutions

TIPRANKS
·
27 Jun

United Therapeutics Corporation Conducted Annual Shareholders Meeting

Reuters
·
27 Jun

United Therapeutics Directors Make Significant Stock Moves!

TIPRANKS
·
26 Jun

Director Nilda Mesa Reports Disposal of Common Shares in United Therapeutics Corporation

Reuters
·
26 Jun

Director Richard Giltner Reports Disposal of United Therapeutics Corporation Common Shares

Reuters
·
26 Jun

United Therapeutics’ Ralinepag Study: A Potential Game-Changer for PAH Treatment

TIPRANKS
·
25 Jun

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

THOMSON REUTERS
·
24 Jun

United Therapeutics and Intermountain Health Partner for Groundbreaking Bioengineered Liver Trial

Reuters
·
24 Jun

Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx

Reuters
·
24 Jun

BRIEF-United Therapeutics Corporation Concludes Enrollment Of The Advance Outcomes Study Of Ralinepag

Reuters
·
23 Jun

United Therapeutics Corp - Advance Outcomes Top-Line Data Is Expected in First Half of 2026

THOMSON REUTERS
·
23 Jun

United Therapeutics Corporation Concludes Enrollment of the Advance Outcomes Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

THOMSON REUTERS
·
23 Jun